Kenvue’s plans to drive sales include re-introducing brands to consumers and making “priority” of 15 brands, most in self care. “Overall, the execution of our recovery plan in the fourth quarter fell short of expectations,” says CEO Thibaut Mongon.
Kenvue Inc. starts its first full year alone with an unexpected outlook, needing to recover the momentum behind the brands former owner Johnson & Johnson made iconic and it counted on to hit the ground running at the top of the consumer health market.
During Kenvue’s earnings briefing for its latest results on 8 February, CEO Thibaut Mongon said the firm's plans to drive...
The gut’s microbiome will shape future medical advances, offering personalized therapies and prevention strategies for a wide range of diseases.
A look at new research on the cardiovascular effects of ADHD medications and what it means for clinical care. This article explores the latest clinical and epidemiological research on the cardiovascular effects of medications commonly prescribed for ADHD, examining potential heart-related risks, underlying mechanisms, and their implications for patient safety, clinical decision-making, and long-term treatment strategies across diverse age groups and risk profiles.
CEO Sue Nabi says Coty has created a “multi-functional, stand-alone organization” within its Consumer Beauty business to drive rapid-fire innovation. In a 20 August presentation, Nabi said the firm’s innovation pipeline undergirds its fiscal 2025 outlook of 6%-8% growth.
The gut’s microbiome will shape future medical advances, offering personalized therapies and prevention strategies for a wide range of diseases.
A look at new research on the cardiovascular effects of ADHD medications and what it means for clinical care. This article explores the latest clinical and epidemiological research on the cardiovascular effects of medications commonly prescribed for ADHD, examining potential heart-related risks, underlying mechanisms, and their implications for patient safety, clinical decision-making, and long-term treatment strategies across diverse age groups and risk profiles.
